Anti-TNF therapy (etanercept, infliximab, adalimumab) has been shown to be well-tolerated in HIV-infected patients, with no enhancement of the rate of opportunistic infections, unless they had uncontrolled HIV replication [104,105,106,107,108]. This evidence concerns the gene TNF and Opportunistic infection.